|
JP2006213721A
|
|
Synthesis of superparamagnetic oxide colloid coated with polysaccharide
|
|
EP1522318A2
|
|
Heat stable coated colloidal iron oxides
|
|
WO9721452A2
|
|
Macromolecular prodrugs of nucleotide analogs
|
|
US5679323A
|
|
Hepatocyte-specific receptor-mediated endocytosis-type compositions
|
|
US5589591A
|
|
Endotoxin-free polysaccharides
|
|
US5554386A
|
|
Delivery of therapeutic agents to receptors using polysaccharides
|
|
EP0713602A1
|
|
Use of polysaccharide covered superparamagnetic oxide colloids
|
|
US5490991A
|
|
Directed delivery of radioprotectants using a receptor specific carrier
|
|
US5314679A
|
|
Vascular magnetic resonance imaging agent comprising nanoparticles
|
|
US5336506A
|
|
Targeting of therapeutic agents using polysaccharides
|
|
US5342607A
|
|
Receptor mediated endocytosis type magnetic resonance imaging contrast agents
|
|
US5352432A
|
|
Hepatocyte specific composition and their use as diagnostic imaging agents
|
|
WO9325239A1
|
|
Arabinogalactan derivatives and uses thereof
|
|
US5478576A
|
|
Arabinogalactan derivatives and uses thereof
|
|
US5219554A
|
|
Hydrated biodegradable superparamagnetic metal oxides
|
|
US5248492A
|
|
Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
|
|
WO9211037A2
|
|
Targeting of therapeutic agents using polysaccharides
|
|
US5284646A
|
|
Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
|
|
US5254460A
|
|
Solvent mediated relaxation assay system
|
|
US5262176A
|
|
Synthesis of polysaccharide covered superparamagnetic oxide colloids
|
